Apotinib 100mg Tablet

Apotinib 100mg tablet is a prescription based medicine used under medical supervision. It is used to treat several types of blood cancer such as blood cancer ( chronic myeloid leukemia, multiple myeloma, bone marrow cancer) and gastrointestinal stromal tumors. Medicine active ingredient is Imatinib, a tyrosine kinase inhibitor. The medicine works by blocking specific protein involved in the growth and proliferation of cancer cells in the body. Doctor's guidance is necessary for determining the appropriate dosage and duration to make the treatment effective.

Chronic myeloid leukemia, multiple myeloma, bone marrow and gastrointestinal stromal tumors.

Apotinib 100mg tablet show various side effects, some patients may experience symptoms but some may not. Many of the symptoms may recover on their own while some take proper treatment:
● Swelling in the face, legs, ankle, and feet
● Nausea, vomiting
● Muscle cramps and pain
● Diarrhea
● Skin rash, night sweats
● Tiredness, dizziness
● Abdominal pain
● Increased weight
● Decreased RBC and WBC cells
● Headache
● Cough, Inflammation in the nose
● Fever, lack of sleep

Apotinib 100mg tablet is an anti-cancer medication. Doctor recommended this to take the medicine with food, at the same time everyday for better efficacy. The correct dosage and duration depend on the patients' medical history. Therefore do not exceed the prescribed dose or continue the medication without medical advice. Taking it in the wrong way may cause serious side effects, so avoid self-medication and use this medication only under the supervision of a qualified healthcare.

Cancer is formed by a protein enzyme which is responsible for the growth of cancer cells. Apotinib 100mg tablet block a specific abnormal protein created by a chromosomal abnormality that signals cancer cell to multiply. It inhibits multiplication and induces cell death in abnormal cancer cells.

• Buchdunger, E., O'Reilley, T., & Wood, J. (2002). Pharmacology of imatinib (STI571). European journal of cancer, 38, S28-S36.
• Lyseng-Williamson, K., & Jarvis, B. (2001). Imatinib. Drugs, 61(12), 1765-1774.
• Peng, B., Lloyd, P., & Schran, H. (2005). Clinical pharmacokinetics of imatinib. Clinical pharmacokinetics, 44(9), 879-894.
• Deininger, M., Buchdunger, E., & Druker, B. J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105(7), 2640-2653.
• Iqbal, N., & Iqbal, N. (2014). Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy research and practice, 2014(1), 357027.